285 related articles for article (PubMed ID: 11991237)
21. Influence of thrombopoietin on platelet activation in myeloproliferative disorders.
Usuki K; Iki S; Endo M; Izutsu K; Inoue K; Nishimura T; Urabe A
Br J Haematol; 1997 Jun; 97(3):530-7. PubMed ID: 9207394
[TBL] [Abstract][Full Text] [Related]
22. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
Shi J; Pipe SW; Rasmussen JT; Heegaard CW; Gilbert GE
J Thromb Haemost; 2008 Jul; 6(7):1167-74. PubMed ID: 18485093
[TBL] [Abstract][Full Text] [Related]
23. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
24. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
25. Formaldehyde-fixation of platelets for flow cytometric measurement of phosphatidylserine exposure is feasible.
Rochat S; Alberio L
Cytometry A; 2015 Jan; 87(1):32-6. PubMed ID: 25266200
[TBL] [Abstract][Full Text] [Related]
26. Correlation between calpain-mediated cytoskeletal degradation and expression of platelet procoagulant activity. A role for the platelet membrane-skeleton in the regulation of membrane lipid asymmetry?
Verhallen PF; Bevers EM; Comfurius P; Zwaal RF
Biochim Biophys Acta; 1987 Sep; 903(1):206-17. PubMed ID: 2820487
[TBL] [Abstract][Full Text] [Related]
27. Factor Xa-driven thrombin generation in plasma: dependency on the aminophospholipid density of membranes and inhibition by phospholipid-binding proteins.
Wielders SJ; Ungethüm L; Reutelingsperger CP; Bevers EM; Lindhout T
Thromb Haemost; 2007 Nov; 98(5):1056-62. PubMed ID: 18000611
[TBL] [Abstract][Full Text] [Related]
28. Variability in platelet procoagulant activity in healthy volunteers.
Sumner WT; Monroe DM; Hoffman M
Thromb Res; 1996 Mar; 81(5):533-43. PubMed ID: 8907312
[TBL] [Abstract][Full Text] [Related]
29. Concurrent and separate inside-out transition of platelet apoptosis and activation markers to the platelet surface.
Mutlu A; Gyulkhandanyan AV; Freedman J; Leytin V
Br J Haematol; 2013 Nov; 163(3):377-84. PubMed ID: 24033315
[TBL] [Abstract][Full Text] [Related]
30. Effect of epinephrine on fibrinogen receptor exposure by aspirin-treated platelets and platelets from concentrates in response to ADP and thrombin.
Peerschke EI
Am J Hematol; 1984 May; 16(4):335-45. PubMed ID: 6326566
[TBL] [Abstract][Full Text] [Related]
31. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity.
Andersen H; Greenberg DL; Fujikawa K; Xu W; Chung DW; Davie EW
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11189-93. PubMed ID: 10500152
[TBL] [Abstract][Full Text] [Related]
32. Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity.
Bevers EM; Tilly RH; Senden JM; Comfurius P; Zwaal RF
Biochemistry; 1989 Mar; 28(6):2382-7. PubMed ID: 2730870
[TBL] [Abstract][Full Text] [Related]
33. Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists.
Corral J; González-Conejero R; Martínez C; Rivera J; Lozano ML; Vicente V
Blood Coagul Fibrinolysis; 2002 Mar; 13(2):95-103. PubMed ID: 11914651
[TBL] [Abstract][Full Text] [Related]
34. Effects of platelets activated by different agonists on fibrin formation and thrombin generation.
Muravlev IA; Dobrovolsky AB; Antonova OA; Khaspekova SG; Mazurov AV
Platelets; 2023 Dec; 34(1):2139365. PubMed ID: 36325627
[TBL] [Abstract][Full Text] [Related]
35. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count.
Gremmel T; Gisslinger B; Gisslinger H; Panzer S
Transl Res; 2018 Oct; 200():35-42. PubMed ID: 30012347
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylserine surface expression and integrin alpha IIb beta 3 activity on thrombin/convulxin stimulated platelets/particles of different sizes.
Rukoyatkina N; Begonja AJ; Geiger J; Eigenthaler M; Walter U; Gambaryan S
Br J Haematol; 2009 Feb; 144(4):591-602. PubMed ID: 19036116
[TBL] [Abstract][Full Text] [Related]
37. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.
Rand ML; Wang H; Pluthero FG; Stafford AR; Ni R; Vaezzadeh N; Allison AC; Kahr WH; Weitz JI; Gross PL
J Thromb Haemost; 2012 Jun; 10(6):1109-19. PubMed ID: 22463102
[TBL] [Abstract][Full Text] [Related]
38. Evidence for a platelet membrane defect in the myeloproliferative syndromes.
Castaldi PA; Berndt MC; Booth W; Gregory C; Bull H; Greaves M
Thromb Res; 1982 Sep; 27(5):601-9. PubMed ID: 6960545
[TBL] [Abstract][Full Text] [Related]
39. Modified phosphatidylethanolamine as the active component of oxidized low density lipoprotein promoting platelet prothrombinase activity.
Zieseniss S; Zahler S; Muller I; Hermetter A; Engelmann B
J Biol Chem; 2001 Jun; 276(23):19828-35. PubMed ID: 11278348
[TBL] [Abstract][Full Text] [Related]
40. Prolonged expression of procoagulant activity of human platelets degranulated by thrombin.
Kinlough-Rathbone RL; Perry DW
Thromb Haemost; 1995 Sep; 74(3):958-61. PubMed ID: 8571329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
